Pediatric Blood & Cancer · 2019 · 45 citations · 9 references
Life SciencesHematologyImmunologyImmunotherapyPediatric HematologyStem Cell TransplantationAutoimmune Disease ImmunotherapyAutoimmune DiseasesAutoimmune Hematologic DiseaseCancer ImmunotherapyHematopoietic Stem Cell Transplant PharmacotherapyTransplant ImmunotherapyAutoimmune MyelofibrosisHematopoietic Stem Cell Transplantation ImmunotherapyHumoral Immunity ImpairmentImmune-mediated CytopeniasImmune-mediated Hemolytic AnemiaImmune-mediated ThrombocytopeniaRefractory Immune ThrombocytopeniaSevere Anemia
Autoimmune cytopenias (AIC) following allogeneic hematopoietic stem cell transplantation (HSCT) may cause significant morbidity and mortality and are often challenging to treat. We present a case of a pediatric patient with primary myelofibrosis of infancy caused by VPS45 protein deficiency, who developed severe refractory hemolytic anemia and immune-mediated thrombocytopenia 3.5 months following HSCT. After the failure of several treatments, he received daratumumab, an anti-CD38 specific antibody, and demonstrated fast and sustained response. The only side effect was delayed recovery of humoral immunity. Daratumumab, by targeting antibody-producing plasma cells, may be a valid treatment option for refractory post-HSCT AIC.
9
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach et al. · New England Journal of Medicine · 2015 · 1.1K citations · Full text